DESC:TECHNICAL FIELD
[0001] The present invention relates, generally, to an endovascular matrix or coating for implanting inside a lumen such as blood vessels or ducts or tracts and, particularly but not exclusively, related to polymeric transferable matrix or coating to treat resistant hypertension by altering the behavior of nerves situated in renal artery.
BACKGROUND
[0002] Resistant hypertension refers to a condition of high blood pressure which is not responding to medication. Renal denervation is a minimally invasive procedure to treat resistant hypertension. This process causes a reduction in the nerve activity, which decreases blood pressure In this process, a form of energy is transferred to the nerves that causes reduction of sympathetic afferent and efferent activity in the nerves and blood pressure can be decreased. .
[0003] Though renal denervation is a minimally invasive procedure, but it has some shortcomings too based on the mode of procedure employed. Commonly used procedures include electromagnetic radiation, ablation through thermal or electric energy etc. However, these cause irreversible and excessive injuries to the efferent (sympathetic) and afferent (sensory) fibers that constitute the renal nerves. This can alter renal function and central hemodynamics. Other possible complications include pseudoaneurysm (a bruise caused by a leaking hole in an artery) and tearing in the renal arteries. Instead of radiation or thermal or electrical energy the application of an active agent, including a chemical compound, pharmaceutical compound or a biological compound, is comparatively safer and can be continuously transferred to lumen, tract or duct for long durations.
[0004] Hence, it is an objective of the invention to provide an endovascular implantable matrix or coating or an active agent containing implantable endovascular matrix or coating that provides controlled release of an active agent at target lesion by bringing an active agent or an active agent containing composition in contact with the target lesion to treat Resistant Hypertension.
SUMMARY OF THE INVENTION
In one aspect of the present invention, an endovascularly implantable matrix for delivering an active agent using a balloon catheter to a lumen is provided. The endovascularly implantable matrix comprises a composition having at least a polymer, at least an active agent, optionally a solvent, and optionally, an additive. The active agent and the polymer in the composition are in a ratio of 5:95 to 70:30. The matrix comprises at least one polymer and at least one active agent. The polymeric matrix may be in the form of a single-layered coating or it may have more than one layer. The polymeric matrix is deployed using a balloon catheter and the matrix is designed in such a way so that it is transferred from the catheter to the target lesion at the time of deployment. The balloon catheter used for deployment of the polymeric matrix includes a hollow inner shaft having an inflation port. The catheter also includes an expandable balloon in fluid communication with the inflation port through the hollow inner shaft and concentrically disposed on to the hollow inner shaft. The polymeric matrix is adhered on periphery of the expandable balloon in such a manner that on expansion of the expandable balloon, by injecting an inflation fluid through the inflation port, allows the polymeric matrix to get adhered on to an inner wall of the lumen, and deflation of the expandable balloon detaches the polymeric matrix from the periphery of the expandable balloon. The transferred detachable polymeric matrix or coating starts diffusing the active agent present in the matrix to the tissues of the artery. The diffused or transferred active agent reaches to the nerves in the artery and reduces their activity.
[0005]
BRIEF DESCRIPTION OF ACCOMPANYING DRAWINGS
[0006] The detailed description is described with reference to the accompanying figures.
FIG. 1 illustrates a detailed view of an endovascularly implantable matrix, according to an embodiment of the present invention;
[0007] FIG. 2 illustrates an accelerated active agent release profile from an endovascularly implantable matrix, according to an embodiment of the present invention; and
[0008] FIG. 3 illustrates a normal porcine serum release profile from an endovascularly implantable matrix, according to an embodiment of the present invention.
DESCRIPTION OF THE INVENTION
[0009] An aspect of the present invention is to address at least the abovementioned problems and/or disadvantages and to provide at least the advantages described below. Wherever possible, the same reference numbers will be used throughout the drawings to refer to the same or the like parts. Wherever possible, corresponding, or similar reference numbers will be used throughout the drawings to refer to the same or corresponding parts.
[0010] Where the term “comprising” is used in the present description and claims, it does not exclude other elements or steps. Where an indefinite or definite article is used when referring to a singular noun, e.g. “a” “an” or “the”, this includes a plural of that noun unless something otherwise is specifically stated. Hence, the term “comprising” should not be interpreted as being restricted to the items listed thereafter; it does not exclude other elements or steps.
[0011] As used herein, the term “an active agent” refers to a chemical compound, any biologically active compound or a pharmaceutical molecule that can be used in the formulation that is suitable for administration in mammals including humans.
[0012] As used herein, the term “lumen” refers to arteries or veins, the term “duct” refers to hollow vessels through which fluid passes from organs e.g. bile duct from liver, the term “tract” refers to hollow organs which may be connected as well e.g. gastrointestinal tract of mammals including humans.
[0013] According to an embodiment of the present disclosure, an endovascularly implantable coating or matrix is provided for deploying a polymeric matrix in a target lesion in a lumen or duct or tract, specifically in an artery, to endovascularly transfer an active agent to the target lesion covered by the polymeric matrix. The endovascularly implantable matrix is deployed using a balloon catheter with an inflatable balloon. The matrix comprises the active agent and the matrix is coated or placed or glued on outer periphery of the balloon. The matrix comprises the active agent either in pure form or in a compositional form. The coated balloon is deflated, folded on pleats and rolled to minimize the profile or cross-sectional diameter of the balloon. The balloon catheter is inserted in a body endovascularly and tracked to the target lesion. Once the balloon reaches the target lesion, the balloon is inflated using an inflation fluid sent to the balloon under high pressure through the inflation port from a handle situated outside the body. The balloon expanded cross-sectionally due to high pressure inflation liquid and comes in contact with the internal wall of the artery. The matrix placed on the outer periphery of the balloon also comes in contact with the internal wall of the artery and gets adhered to the same. On deflation of the balloon, the profile of the balloon reduces, and the matrix detaches from the outer peripheral surface of the balloon and adheres with the inner wall of the artery in form of a continuous film or patches. The active agent present in the matrix starts transferring the active agent to the tissues of the inner wall of the artery on contact and continues the active agent delivery over a period of time. The active agent transfers from the polymeric matrix to the artery tissues through absorption and diffusion due to concentration difference. The transferred active agent may be targeted to the entire surface area of the inner wall of the artery or to specific targeted points on the inner wall of the artery or within the wall of the artery. The active agent chemically or biologically reacts with specific nerves, molecules, cells or cell manufacturing matter to eliminate of change them to alter specific symptoms.
[0014] According to an embodiment of the present disclosure, the matrix is a single or multiple layered structure made of only active agent or active agent containing composition. In another embodiment of the present disclosure, the active agent containing composition is a polymeric matrix in which the active agent is dispersed throughout the polymeric matrix. In addition, the polymeric matrix may have more than one active agent as well. The other active agent may be targeted to same symptoms or different symptoms or to treat the aftereffects generated due to sheet deployment or due to action of the active agent. Further, the polymeric matrix may also have additional additives to enhance other required properties. These additives include, but not limited to, plasticizer, antioxidant, filler, lipophilic agent, hydrophilic agent, spacer agent, osmogenes, salts or combinations thereof.
[0015] Further, the polymeric matrix comprises a biodegradable polymer or a plurality of different biodegradable polymeric materials. The polymeric matrix is placed on the outer periphery of a balloon catheter and tracked endovascularly to an artery, specifically a renal artery. By controlling different structural configurations and ratio of components in the polymeric matrix, the rate of release of the active agent can be controlled and a prolonged active agent delivery is achieved.
[0016] According to an embodiment of the present disclosure, the polymeric matrix is made of a composition comprising a biodegradable polymer, an active agent and a solvent. The polymeric matrix is transportable to the target lesion site endovascularly in the artery, specifically the renal artery, through an appropriate catheter. At the target lesion site, the polymeric matrix either can be put as a patch or a film or a composite layer or in a semi-solid gel-like form.
[0017] According to an embodiment of the present disclosure, the solvent is selected from water, polymeric solvent, non-polymeric solvent, saline, biodegradable polymeric liquid or a mixture thereof.
[0018] According to an embodiment of the present disclosure, the polymeric matrix comprises a plurality of layers.
[0019] According to another embodiment of the present disclosure, active agent present in the polymeric matrix may be in form of transferable micro-sized geometric indentations protruding from a surface of the polymeric matrix and these indentations are made of pure active agent or active agent filled polymeric cones.
[0020] According to an embodiment of the present disclosure, the polymeric matrix comprises poly lactide-co-caprolactone and the active agent is sirolimus. The drug to polymer ratio in this polymeric composition is between 5:95 to 70:30. The polymeric matrix is designed to release the active agent in two phases where both the phases have differing rate of controlled release and the rate of the active agent release in a first phase is higher than a second phase. Higher release rate of the active agent in the first phase ensures required drug transfer and retention while a slower but sustained release of the active agent in the second phase replenishes the consumed quantity of the active agent over a period of time. The amount of active agent release in the first phase varies from 15 weight percent to 50 weight percent, specifically 20 weight percent to 40 weight percent of the total amount of the drug present in the polymeric matrix.
[0021] Explained below is an exemplary embodiment of the present disclosure. As illustrated in Fig. 1, an endovascularly implantable matrix for delivering an active agent to a lumen (116) using a balloon catheter (100) is provided. The endovascularly implantable matrix comprises a composition having at least a polymer, at least an active agent, optionally a solvent, and optionally, an additive. The active agent and the polymer in the composition are in a ratio of 5:95 to 70:30. The catheter 100 having a handle 102, a hollow catheter shaft 104, a hollow inner shaft 106, an expandable balloon 108, an inflation port 110, a guidewire port 112 and an active agent containing polymeric matrix 114. The catheters 100 are medical devices that can be inserted in a body (not shown) to treat diseases or perform a surgical procedure. The expandable balloon 108 is tracked to a target lesion in a lumen 116, specifically in a renal artery, endovascularly by the catheter 100. More particularly, the expandable balloon 108 is delivered to the target lesion in the lumen 116 by the catheter 100 such that the active agent containing polymeric matrix 114 contacts an internal wall of the lumen 116 at the target lesion.
[0022] The catheter 100, as shown in Figure 1, has a proximal end of the hollow inner shaft 106 that is connected to the handle 102 and it extends through the hollow catheter shaft 104 till other end 118. Further, a proximal end of the handle 102 has an inflation port 110 and a guidewire port 112. The hollow catheter shaft 104 has its proximal end attached to the inflation port 110 situated in the handle 102 in such a way so that it is in fluid communication throughout a length the catheter 100. The hollow catheter shaft 104 is connected to a proximal end of the expandable balloon 108 at its distal end. The outer peripheral surface of the expandable balloon 108 is coated with the active agent containing polymeric matrix 114 that on expanding the expandable balloon 108 comes in contact with the inner wall of the lumen 116, adheres with the inner wall of the lumen 116 and detaches from the outer surface of the expandable balloon 108. Once attached, the active agent that is present in the polymeric matrix 114, starts absorbing in the artery wall. The polymeric matrix 114 is usually in shape of a continuous film or patch.
[0023] In the illustrated embodiment, an outer surface of expandable balloon 108 includes a single layer of active agent dispersed polymeric matrix 114 or multiple layers of active agent dispersed polymeric matrix 114 containing constituents in varying ratio in comparison to adjacent layer or layers. In addition, one or more layers in the multiple structure may have at least one constituent completely different from the adjacent layer or layers. Further, biocompatible or biodegradable adhesive, dissolvable/non-dissolvable stitches, staples, or sutures can be used with the polymeric matrix 114 to ensure attachment of the sheet with the inner wall of the lumen 116 after the procedure.
[0024] In other embodiment, the polymeric matrix may be made up of an active agent dispersed polymeric matrix 114 where there may be more than one active agent to treat the effects generated due to patch deployment or due to action of nerve-specific active agent. Further, the polymeric matrix 114 may comprise a single biodegradable polymer or a combination of two or more biodegradable polymeric materials. By controlling different structural properties and ratio of polymeric mixture; the rate of release of the active agent may be controlled and a prolonged drug delivery is achieved.
[0025] Fig. 2 illustrates an active agent release profile of a sirolimus containing poly lactide-co-caprolactone (95/5) based polymeric matrix placed in a testing environment (in-vitro). The release medium is a simulated biological fluid. The release profile is studied in accelerated condition for a duration of 24 hours. The release medium for accelerated study is a mixture of phosphate buffer saline, non-ionic surfactant and an organic solvent. The pH of the solution is kept at 7.4 and the release study is studied at 37° C temperature to mimic temperature of a normal human body. The active agent release profile clearly shows two phases of active agent release: the rate of release of the active agent is higher in the first phase (in first hour) then the second phase of slower and sustained release over a total duration of 24 hours.
[0026] Fig. 3 illustrates an active agent release profile of a sirolimus containing poly lactide-co-caprolactone (95/5) based polymeric matrix placed in a testing environment (in-vitro). The release medium is porcine serum. The release profile is studied for a duration of three days. Similar to the accelerated study, the active agent release profile clearly shows two phases: the rate of release of the active agent is higher in the first phase (day 1) than the second phase of slower and sustained release over next two days.
[0027] According to an embodiment of the present disclosure, the polymer is selected from, but not limited to, biodegradable polymers, non-biodegradable polymers, polymers of L-lactide, Glycolide or combinations thereof, poly(hydroxybutyrate), polyorthoesters, poly anhydrides, poly(glycolic acid), poly(glycolide), poly(L-lactic acid), poly(L-lactide), poly(D-lactic acid), poly(D-lactide), poly(caprolactone), poly(trimethylene carbonate), polyester amide, polyesters, polyolefins, polycarbonates, polyoxymethylenes, polyimides, polyethers, and copolymers and combinations thereof.
[0028] According to an embodiment of the present disclosure, the active agent is selected from, but not limited to, anti-restenosis drugs, Neurolytic agents, Quaternary ammonium salts, Sodium Channel Blockers, Anesthetics, Conductive Fluids, Amino Acids, Amines, Calcium Channel Blockers, neurotoxins, venom, neuromodulators, neurotransmitters, Diuretics, Heated fluids e.g. Saline, Hypotonic Fluids, Vasovasorum Constrictors, Neurotransmitter Chemicals, Venom, Sclerosant Agents, Anti-Nerve Growth Agents, Aminosteroids, Neurotoxins, Alcohols, 6-Hydroxydopamine, Acebutolol, Acetic Acid, Acetic Anhydride, Acetyl Chloride, Acetylcholine, Adenosine, Aflatoxins, Ambrisentan, Amiloride, Amiodarone, Amlodipine, Ammonia, Anti-Acetylcholinesterase, Anti-Dopamine Beta-Hydroxylase, Anti-Dopamine Beta-Hydroxylase Immunotoxin (DHIT), Anti-Dopamine Beta-Hydroxylase Saporin (DBH-SAP), Argon, Arsenic, Atenolol, Azitoxin, Benazepril, Benzocaine, Bepridil, Betanidine, Betaxolol, Bisoprolol, Bleomycin, Bosentan, Botulinum toxin, Bretylium Tosylate, BuLi, Bungarotoxin, Bupivacaine, Bupranolol hydrochloride, Butanol, Ca(OH)2, Caffeine, Calciceptin, Calcycludin, Capsaicin, Carbamazepine, Carbon Dioxide, Cardiac Glycoside, Caribodotoxin, Carteolol, Carteolol hydrochloride, Catopril, Cetylcholine, Cevacine, Cevadine, Chloroquine, Chlorotoxin, Clonidine, Conotoxin, Curare, Cymarins, Cytochalasin D, Debrisoquine, Decarbamoyl Saxitoxins, Dibucaine, Digitalis, Digitoxins, Digoxins, Diltiazem, Dimethyl Sulfoxide, Diprophylline, Disopyramide, Dobutamine hydrochloride, Domoic Acids, Dopamine hydrochloride, Doxazosin, Doxycycline, Enalapril, Enalaprilat, Encainide, Epinephrin, Esmolol, Ethanol, Ethanolamine Oleate, Ethyl Acetate, Ethyl Chloroformate, Ethyl Iodide, Ethyl Lactate, Ethyl Nitrate, Ethylene glycol, Everolimus, Felodipine, Fimolol, Flecainide, Fosinopril, Furosemide, Glutamate, Glycerin, Glycerol, Guanabenz, Guanacline, Guanadrel, Guanazodine, Guanethidine, Guanethidine Sulfates, Guanfacine, Guanidinium, Guanoclor, Guanoxabenz, Guanoxan, H2O2, Helium, Hexane, Hydriodic Acid, Hydrobromic Acid, Hydrochloric Acid, Hypertonic Saline, Indoramin, Isobutanol, Isopropanol, Isopropyl Acetate, Isopropyl Iodide, Isoquinoline, Isradipine, K2CO3, Ketanserin, KH, KOH, Labetalol, Lactic Acid, Laureth (Polidocanol), Leptocurare, Lidocaine, Lipiodol, Lisinopril, Losartan, Malonic Acid, Malonyl Chloride, Margatoxin, Maurotoxin, Mecamylamine, Methanol, Methyl Acetate, Methyldopa, Metildigoxin, Metirosine, Metoprolol, Metoprolol tartrate, Mexiletine, Minosteroids, Moexipril, Moricizine, Morrhuate Sodium, Moxonidine, Mycophenolic Acid, N-(2-Chloroethyl)-N-Ethyl-2-Bromobenzylamine (DSP4), Nadolol, NaH, NaHCO3, NaOEt, NaOH, NaSEt, Neosaxitoxins, NH4OH, Nicardipine, Nifedipine, Nimodipine, Nitric Acid, Nitric oxide, Nitrogen, Nitrous Acid, N-Methyl-(R)-Sarsolinol, Octopamine hydrochloride, Oleandrins, Ouabin, Oxalic Acid, Oxprenolol hydrochloride, Oxygen, Oxytetracycline, Pachycurare, Paclitaxel, Pargyline, Penbatolol, Peracetic Acid, Perchloric Acid, Phenol, Phentolamine, Pheoxybenzamine, Phosphoric Acid, Phtx3 (Phoneutria toxin), Pindolol, Polidocanol, Potassium Chloride, Povidone Iodine, Prazosin, Prazosin hydrochloride, Prazosin Plus Polythiazide, Procainamide, Propafenone, Propanol, Propranolol, Propranolol hydrochloride, Propyl Iodide, Proscillaridin, Pyruvic Acid, Quabains, Quinacrine, Quinapril, Quinidine, Quinine, Ramipril, Relmenidine, Rescinnamine, Reserpine, Resiniferatoxin, Saline, Saxitoxins, Sirolimus, MK-0431 (Sitagliptin phosphate), Sitaxentan, slatatoxin, Slototoxin, Sodium Chloride (Salt), Sodium Morrhuate, Sodium Tetradecyl Sulfate, Sotalol, Staurosporines, Sulfuric Acid, Talc, Taxol, Terazosin, Tetanus Toxin, Tetracaine, Tetracycline, Tetraethylammonium, Tetrodotoxin, Tocainide, Trichlormethiazide, Trimazosin, Trimethaphan, Tycatoxin, Ubidecarenon, Urapidil, Urea, Vanilloids, Vanilloylzygadenine, Heftoxin, Verapamils, Veratridine, Veratroylzygadenine with saline solution, Vinblastin, Vincristine, Zotarolimus, Zygacine, ß-carboline derivative, ?-conotoxin, Heparinized Saline, Butorakotoshkin, neuromodulators, botulinum oxide or combinations thereof.
[0029] The endovascularly implantable matrix of the present invention is used for delivery of the active agent that is achieved successfully by endovascular deployment of the polymeric matrix using a balloon catheter in an artery. The arteries may be femoral artery, renal artery, superficial femoral artery, popliteal artery, tibial artery, genicular artery, cerebral artery, carotid artery, vertebral artery, subclavian artery, radial artery, brachial artery, axillary artery, coronary artery, peripheral artery, iliac artery, or neuro-arteries. For example, the renal denervation catheter may be used in chemical renal denervation procedure.
[0030]
[0031] According to an embodiment of the present disclosure, the non-ionic surfactant is selected from, but not limited to, different grades from a surfactant family selected from Tween, Brij, and Triton. The organic solvent is selected from, but not limited to, methanol, ethanol, Allyl alcohol, Ethanolamine, Hexane, Heptane, Cyclohexane, 1-octanol, Pentane, Xylene Acetone, Acetonitrile, Tetrahydrofuran, Nitromethane, chloroform, Dichloromethane, Ethyl acetate, or combinations thereof.
[0032] Active agent based renal denervation procedures provide better precision in terms of delivery location and the amount of active agent that need to be delivered. Also, it allows parallel or follow-up administration of medication at the target lesion to treat after-effects of the procedure. In addition, in some embodiments, this administration can be prolonged for a specific time duration. Hence, active agent based renal denervation provides a better alternative to traditional denervation systems to achieve dose-dependent, predictable, safe and essentially painless renal denervation.
[0033] In the above description, for purpose of explanation, specific details are set forth in order to provide an understanding of the present disclosure. It will be apparent, however, to one skilled in the art that the present disclosure may be practiced without these details. One skilled in the art will recognize that embodiments of the present disclosure, one of which is described below, may be incorporated into a number of systems. Further, structures and devices shown in the figures are illustrative of exemplary embodiment of the present disclosure and are meant to avoid obscuring the present disclosure.
DESCRIPTION OF REFERENCE CHARACTER
100 Catheter
102 Handle
104 Hollow Catheter Shaft
106 Hollow Inner Shaft
108 Expandable Balloon
110 Inflation Port
112 Guidewire Port
114 Polymeric Matrix
116 Lumen
118 Other End of Hollow Catheter Shaft
,CLAIMS:
1. An endovascularly implantable matrix for delivering an active agent to a lumen (116) using a balloon catheter, the endovascularly implantable matrix comprising a composition having:
at least a polymer;
at least an active agent;
optionally a solvent; and
optionally, an additive,
wherein the active agent and the polymer in the composition are in a ratio of 5:95 to 70:30.

2. The endovascularly implantable matrix as claimed in claim 1, wherein the matrix comprises a plurality of layers.
3. The endovascularly implantable matrix as claimed in claim 1, wherein the polymer comprised in the composition is selected from a biodegradable polymer, a non-biodegradable polymer or combinations thereof.

4. The endovascularly implantable matrix as claimed in claim 1, wherein the active agent is selected from anti-restenosis drugs, Neurolytic agents, Quaternary ammonium salts, Sodium Channel Blockers, Anesthetics, Conductive Fluids, Amino Acids, Amines, Calcium Channel Blockers, neurotoxins, venom, neuromodulators, neurotransmitters, Diuretics, Saline, Hypotonic Fluids, Vasovasorum Constrictors, Neurotransmitter Chemicals, Venom, Sclerosant Agents, Anti-Nerve Growth Agents, Aminosteroids, Neurotoxins, Alcohols, 6-Hydroxydopamine, Acebutolol, Acetic Acid, Acetic Anhydride, Acetyl Chloride, Acetylcholine, Adenosine, Aflatoxins, Ambrisentan, Amiloride, Amiodarone, Amlodipine, Ammonia, Acetylcholinesterase, Anti-Dopamine, Beta-Hydroxylase, Anti-Dopamine Beta-Hydroxylase Immunotoxin, Beta-Hydroxylase Saporin, Argon, Arsenic, Atenolol, Azitoxin, Benazepril, Benzocaine, Bepridil, Betanidine, Betaxolol, Bisoprolol, Bleomycin, Bosentan, Botulinum toxin, Bretylium Tosylate, BuLi, Bungarotoxin, Bupivacaine, Bupranolol hydrochloride, Butanol, calcium hydroxide, Caffeine, Calciceptin, Calcycludin, Capsaicin, Carbamazepine, Carbon Dioxide, Cardiac Glycoside, Caribodotoxin, Carteolol, Carteolol hydrochloride, Catopril, Cetylcholine, Cevacine, Cevadine, Chloroquine, Chlorotoxin, Clonidine, Conotoxin, Curare, Cymarins, Cytochalasin D, Debrisoquine, Decarbamoyl Saxitoxins, Dibucaine, Digitalis, Digitoxins, Digoxins, Diltiazem, Dimethyl Sulfoxide, Diprophylline, Disopyramide, Dobutamine hydrochloride, Domoic Acids, Dopamine hydrochloride, Doxazosin, Doxycycline, Enalapril, Enalaprilat, Encainide, Epinephrin, Esmolol, Ethanol, Ethanolamine Oleate, Ethyl Acetate, Ethyl Chloroformate, Ethyl Iodide, Ethyl Lactate, Ethyl Nitrate, Ethylene glycol, Everolimus, Felodipine, Fimolol, Flecainide, Fosinopril, Furosemide, Glutamate, Glycerin, Glycerol, Guanabenz, Guanacline, Guanadrel, Guanazodine, Guanethidine, Guanethidine Sulfates, Guanfacine, Guanidinium, Guanoclor, Guanoxabenz, Guanoxan, hydrogen peroxide, Helium, Hexane, Hydriodic Acid, Hydrobromic Acid, Hydrochloric Acid, Hypertonic Saline, Indoramin, Isobutanol, Isopropanol, Isopropyl Acetate, Isopropyl Iodide, Isoquinoline, Isradipine, potassium carbonate, Ketanserin, potassium hydride, potassium hydroxide, Labetalol, Lactic Acid, Laureth, Leptocurare, Lidocaine, Lipiodol, Lisinopril, Losartan, Malonic Acid, Malonyl Chloride, Margatoxin, Maurotoxin, Mecamylamine, Methanol, Methyl Acetate, Methyldopa, Metildigoxin, Metirosine, Metoprolol, Metoprolol tartrate, Mexiletine, Minosteroids, Moexipril, Moricizine, Morrhuate Sodium, Moxonidine, Mycophenolic Acid, N-(2-Chloroethyl)-N-Ethyl-2-Bromobenzylamine, Nadolol, sodium hydride, sodium bicarbonate, NaOEt, NaSEt, Neosaxitoxins, ammonium hydroxide, Nicardipine, Nifedipine, Nimodipine, Nitric Acid, Nitric oxide, Nitrogen, Nitrous Acid, N-Methyl-(R)-Sarsolinol, Octopamine hydrochloride, Oleandrins, Ouabin, Oxalic Acid, Oxprenolol hydrochloride, Oxygen, Oxytetracycline, Pachycurare, Paclitaxel, Pargyline, Penbatolol, Peracetic Acid, Perchloric Acid, Phenol, Phentolamine, Pheoxybenzamine, Phosphoric Acid, Phoneutria toxin, Pindolol, Polidocanol, Potassium Chloride, Povidone Iodine, Prazosin, Prazosin hydrochloride, Prazosin Plus Polythiazide, Procainamide, Propafenone, Propanol, Propranolol, Propranolol hydrochloride, Propyl Iodide, Proscillaridin, Pyruvic Acid, Quabains, Quinacrine, Quinapril, Quinidine, Quinine, Ramipril, Relmenidine, Rescinnamine, Reserpine, Resiniferatoxin, Saline, Saxitoxins, Sirolimus, Sitagliptin phosphate, Sitaxentan, slatatoxin, Slototoxin, Sodium Chloride, Sodium Morrhuate, Sodium Tetradecyl Sulfate, Sotalol, Staurosporines, Sulfuric Acid, Talc, Taxol, Terazosin, Tetanus Toxin, Tetracaine, Tetracycline, Tetraethylammonium, Tetrodotoxin, Tocainide, Trichlormethiazide, Trimazosin, Trimethaphan, Tycatoxin, Ubidecarenon, Urapidil, Urea, Vanilloids, Vanilloylzygadenine, Heftoxin, Verapamils, Veratridine, Veratroylzygadenine with saline solution, Vinblastin, Vincristine, Zotarolimus, Zygacine, ß-carboline derivative, ?-conotoxin, Heparinized Saline, Butorakotoshkin, neuromodulators, botulinum oxide or a combination thereof.

5. The endovascularly implantable matrix as claimed in claim 1, wherein the polymer is selected from one or more of poly-L-lactide, poly(hydroxybutyrate), polyorthoesters, poly anhydrides, poly(glycolic acid), poly(glycolide), poly(L-lactic acid), poly(D-lactic acid), poly(D-lactide), poly(caprolactone), poly(trimethylene carbonate), polyester amide, polyesters, polyolefins, polycarbonates, polyoxymethylenes, polyimides, polyethers, their copolymers or terpolymers or a combinations thereof.

6. The endovascularly implantable matrix as claimed in claim 1, wherein the solvent for the composition is selected from one or more of water, polymeric solvent, non-polymeric solvent, saline, biodegradable polymeric liquid, or a mixture thereof.

7. The endovascularly implantable matrix as claimed in claim 1 wherein the matrix is implanted in a lumen selected from femoral artery, renal artery, superficial femoral artery, popliteal artery, tibial artery, genicular artery, cerebral artery, carotid artery, vertebral artery, subclavian artery, radial artery, brachial artery, axillary artery, coronary artery, peripheral artery, iliac artery, neuro-artery, or combinations thereof.